Which has higher earnings and valuation, GMAB or INDV?

Genmab A/S has higher revenue and earnings than Indivior. Genmab A/S is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.90B 4.17 $963M $1.32 19.78 Indivior $1.29B 3.95 $210M $1.95 21.45

Is GMAB or INDV more profitable?

Genmab A/S has a net margin of 21.05% compared to Indivior's net margin of 19.44%. Genmab A/S's return on equity of 15.34% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Indivior 19.44% -219.26% 29.40%

Does the media refer more to GMAB or INDV?

In the previous week, Genmab A/S had 6 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Genmab A/S and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat Genmab A/S's score of -0.19 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ASND or INDV?

Indivior has higher revenue and earnings than Ascendis Pharma A/S. Indivior is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 19.97 -$258M $8.67 30.07 Indivior $1.29B 3.95 $210M $1.95 21.45

Does the media refer more to ASND or INDV?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat Ascendis Pharma A/S's score of 0.45 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BBIO or INDV?

Indivior has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 27.40 -$724.93M -$3.74 N/A Indivior $1.29B 3.95 $210M $1.95 21.45

Does the media refer more to BBIO or INDV?

In the previous week, BridgeBio Pharma had 9 more articles in the media than Indivior. MarketBeat recorded 11 mentions for BridgeBio Pharma and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat BridgeBio Pharma's score of -0.02 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or INDV?

In the previous week, Axsome Therapeutics had 2 more articles in the media than Indivior. MarketBeat recorded 4 mentions for Axsome Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat Axsome Therapeutics' score of 0.50 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or INDV?

In the previous week, Elanco Animal Health had 1 more articles in the media than Indivior. MarketBeat recorded 3 mentions for Elanco Animal Health and 2 mentions for Indivior. Elanco Animal Health's average media sentiment score of 1.38 beat Indivior's score of 0.72 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Indivior (INDV) Competitors

$41.83 +0.54 (+1.31%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$41.90 +0.07 (+0.17%)

As of 06/26/2026 07:59 PM Eastern

Compare

INDV vs. GMAB, ASND, BBIO, AXSM, and ELAN

Should you buy Indivior stock or one of its competitors? MarketBeat compares Indivior with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indivior include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Indivior compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Genmab A/S has a net margin of 21.05% compared to Indivior's net margin of 19.44%. Genmab A/S's return on equity of 15.34% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Indivior	19.44%	-219.26%	29.40%

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Indivior. Genmab A/S is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.17	$963M	$1.32	19.78
Indivior	$1.29B	3.95	$210M	$1.95	21.45

Genmab A/S presently has a consensus price target of $37.93, indicating a potential upside of 45.29%. Indivior has a consensus price target of $40.29, indicating a potential downside of 3.69%. Given Genmab A/S's higher probable upside, research analysts clearly believe Genmab A/S is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Genmab A/S had 6 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Genmab A/S and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat Genmab A/S's score of -0.19 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Summary

Genmab A/S beats Indivior on 9 of the 16 factors compared between the two stocks.

How does Indivior compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Ascendis Pharma A/S currently has a consensus target price of $295.39, indicating a potential upside of 13.28%. Indivior has a consensus target price of $40.29, indicating a potential downside of 3.69%. Given Ascendis Pharma A/S's higher possible upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has higher revenue and earnings than Ascendis Pharma A/S. Indivior is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.97	-$258M	$8.67	30.07
Indivior	$1.29B	3.95	$210M	$1.95	21.45

Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat Ascendis Pharma A/S's score of 0.45 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.3% of Indivior shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 57.87% compared to Indivior's net margin of 19.44%. Ascendis Pharma A/S's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Indivior	19.44%	-219.26%	29.40%

Summary

Ascendis Pharma A/S beats Indivior on 10 of the 16 factors compared between the two stocks.

How does Indivior compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 9 more articles in the media than Indivior. MarketBeat recorded 11 mentions for BridgeBio Pharma and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat BridgeBio Pharma's score of -0.02 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	27.40	-$724.93M	-$3.74	N/A
Indivior	$1.29B	3.95	$210M	$1.95	21.45

BridgeBio Pharma presently has a consensus price target of $92.90, indicating a potential upside of 32.26%. Indivior has a consensus price target of $40.29, indicating a potential downside of 3.69%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has a net margin of 19.44% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Indivior	19.44%	-219.26%	29.40%

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Indivior beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does Indivior compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Indivior has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.52	-$183.17M	-$3.73	N/A
Indivior	$1.29B	3.95	$210M	$1.95	21.45

Axsome Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 2 more articles in the media than Indivior. MarketBeat recorded 4 mentions for Axsome Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat Axsome Therapeutics' score of 0.50 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics presently has a consensus price target of $258.95, suggesting a potential upside of 6.94%. Indivior has a consensus price target of $40.29, suggesting a potential downside of 3.69%. Given Axsome Therapeutics' higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has a net margin of 19.44% compared to Axsome Therapeutics' net margin of -26.59%. Indivior's return on equity of -219.26% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Indivior	19.44%	-219.26%	29.40%

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Indivior beats Axsome Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Indivior compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Elanco Animal Health had 1 more articles in the media than Indivior. MarketBeat recorded 3 mentions for Elanco Animal Health and 2 mentions for Indivior. Elanco Animal Health's average media sentiment score of 1.38 beat Indivior's score of 0.72 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Indivior has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.60	-$232M	-$0.50	N/A
Indivior	$1.29B	3.95	$210M	$1.95	21.45

Indivior has a net margin of 19.44% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Indivior	19.44%	-219.26%	29.40%

Elanco Animal Health has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Indivior has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Elanco Animal Health currently has a consensus price target of $28.55, indicating a potential upside of 16.23%. Indivior has a consensus price target of $40.29, indicating a potential downside of 3.69%. Given Elanco Animal Health's higher probable upside, equities analysts plainly believe Elanco Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Elanco Animal Health beats Indivior on 9 of the 16 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDV vs. The Competition

Export

Metric	Indivior	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.10B	$3.01B	$6.78B	$12.22B
Dividend Yield	N/A	1.77%	2.67%	6.13%
P/E Ratio	21.45	19.54	25.90	24.18
Price / Sales	3.95	461.90	579.22	113.32
Price / Cash	15.18	56.66	46.99	54.37
Price / Book	-53.63	4.21	10.78	6.36
Net Income	$210M	$64.45M	$3.58B	$337.99M
7 Day Performance	9.27%	2.22%	2.22%	0.10%
1 Month Performance	12.72%	1.36%	1.12%	-0.11%
1 Year Performance	199.86%	29.73%	34.29%	27.61%

Indivior Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDV Indivior	2.1717 of 5 stars	$41.83 +1.3%	$40.29 -3.7%	+205.6%	$5.10B	$1.29B	21.45	1,051	News Coverage Analyst Upgrade High Trading Volume
GMAB Genmab A/S	4.5906 of 5 stars	$24.32 -1.0%	$37.93 +55.9%	+25.9%	$15.16B	$3.72B	18.42	3,029	Analyst Forecast Options Volume Analyst Revision Gap Down
ASND Ascendis Pharma A/S	4.3796 of 5 stars	$223.17 -0.1%	$295.39 +32.4%	+50.8%	$13.94B	$814.57M	25.77	1,189	News Coverage
BBIO BridgeBio Pharma	2.9324 of 5 stars	$67.50 -0.7%	$89.14 +32.1%	+55.7%	$13.20B	$502.08M	N/A	400	Insider Trade
AXSM Axsome Therapeutics	2.0254 of 5 stars	$249.99 -1.3%	$256.79 +2.7%	+136.1%	$12.83B	$638.50M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDV) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indivior (INDV) Competitors

INDV vs. GMAB, ASND, BBIO, AXSM, and ELAN

How does Indivior compare to Genmab A/S?

Summary

How does Indivior compare to Ascendis Pharma A/S?

Summary

How does Indivior compare to BridgeBio Pharma?

Summary

How does Indivior compare to Axsome Therapeutics?

Summary

How does Indivior compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indivior (INDV) Competitors

INDV vs. GMAB, ASND, BBIO, AXSM, and ELAN

How does Indivior compare to Genmab A/S?

Is GMAB or INDV more profitable?

Do institutionals and insiders believe in GMAB or INDV?

Which has higher earnings and valuation, GMAB or INDV?

Do analysts prefer GMAB or INDV?

Does the media refer more to GMAB or INDV?

Which has more volatility and risk, GMAB or INDV?

Summary

How does Indivior compare to Ascendis Pharma A/S?

Do analysts rate ASND or INDV?

Which has preferable valuation & earnings, ASND or INDV?

Which has more volatility and risk, ASND or INDV?

Does the media refer more to ASND or INDV?

Do insiders and institutionals believe in ASND or INDV?

Is ASND or INDV more profitable?

Summary

How does Indivior compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or INDV?

Does the media refer more to BBIO or INDV?

Which has better earnings and valuation, BBIO or INDV?

Do analysts rate BBIO or INDV?

Is BBIO or INDV more profitable?

Do insiders & institutionals believe in BBIO or INDV?

Summary

How does Indivior compare to Axsome Therapeutics?

Which has better valuation and earnings, AXSM or INDV?

Which has more volatility & risk, AXSM or INDV?

Does the media favor AXSM or INDV?

Do analysts recommend AXSM or INDV?

Is AXSM or INDV more profitable?

Do insiders and institutionals have more ownership in AXSM or INDV?

Summary

How does Indivior compare to Elanco Animal Health?

Does the media favor ELAN or INDV?

Do institutionals and insiders have more ownership in ELAN or INDV?

Which has stronger valuation and earnings, ELAN or INDV?

Is ELAN or INDV more profitable?

Which has more volatility and risk, ELAN or INDV?

Do analysts prefer ELAN or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools